Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Tumor characteristics of the BCAC study subjects

From: Patient survival and tumor characteristics associated with CHEK2:p.I157T – findings from the Breast Cancer Association Consortium

  Non-carriers p.I157T carriers c.1100delC carriers p value (I157T/nc) p value (I157T/1100delC) p value (1100delC/nc)
ER Negative 4595 85 26 0.00046 0.61 0.0015
20.2 % 15.5 % 11.2 %
Positive 18,179 462 207
79.8 % 84.5 % 88.8 %
Missing 3166 43 38    
12.2 % 7.3 % 14.0 %
PR Negative 6397 147 44 0.0034 0.90 0.0045
32.7 % 28.5 % 23.3 %
Positive 13,173 368 145
67.3 % 71.5 % 76.7 %
Missing 6370 75 82    
24.6 % 12.7 % 30.3 %
Her2 Negative 8220 231 95 0.68 0.10 0.24
84.7 % 83.7 % 81.9 %
Positive 1483 45 21
15.3 % 16.3 % 18.1 %
Missing 16,237 314 155    
62.6 % 53.2 % 57.2 %
EGFR Negative 3841 122 62 0.21 0.26 0.034
89.6 % 90.4 % 96.9 %
Positive 448 13 2
10.4 % 9.6 % 3.1 %
Missing 21,651 455 207    
83.5 % 77.1 % 76.4 %
CK5/6 Negative 4734 143 80 0.30 0.29 0.19
87.9 % 88.3 % 92.0 %
Positive 652 19 7
12.1 % 11.7 % 8.0 %
Missing 20,554 428 184    
79.2 % 72.5 % 67.9 %
TP53 Negative 3755 144 88 0.00048 0.21 0.16
81.6 % 90.6 % 86.3 %
Positive 847 15 14
18.4 % 9.4 % 13.7 %
Missing 21,338 431 169    
82.3 % 73.1 % 62.4 %
Tumor size (ordinal) <20 mm 14,949 340 149 0.29 0.33 0.83
65.6 % 65.6 % 62.6 %
20–50 mm 6953 162 82
30.5 % 31.3 % 34.5 %
>50 mm 876 16 7
3.8 % 3.1 % 2.9 %
Missing 3162 72 33    
12.2 % 12.2 % 12.2 %
Lymph node status Negative 13,144 320 125 0.94 0.91 0.64
62.0 % 60.4 % 57.6 %
Positive 8070 210 92
38.0 % 39.6 % 42.4 %
Missing 4726 60 54    
18.2 % 10.2 % 19.9 %
Grade (ordinal) 1 4916 132 38 0.00023 0.0030 0.38
22.5 % 26.7 % 17.4 %
2 10,817 266 127
49.6 % 53.7 % 58.0 %
3 6089 97 54    
27.9 % 19.6 % 24.7 %
Missing 4118 95 52    
15.9 % 16.1 % 19.2 %
Histological type Ductal 14,133 273 193 0.0044* 0.0010# 0.67#
72.7 % 60.0 % 76.9 %
Lobular 2966 100 36
15.3 % 22.0 % 14.3 %
Mixed (ductal and lobular) 455 26 4
2.5 % 6.0 % 1.7 %
Tubular 271 17 2
1.5 % 4.0 % 0.7 %
Medullary 177 4 3
1.0 % 0.9 % 1.7 %
Mucinous 213 9 3
1.2 % 2.1 % 1.4 %
Papillary 55 1 1
0.3 % 0.2 % 1.8 %
Missing† 7670 160 29    
29.6 % 27.1 % 10.7 %
Subtype‡ LumA (ER+, PR+, Her2-) 5415 164 72 0.00089 0.46 0.0087
58.9 % 63.6 % 65.5 %
LumB (ER+, PR-, Her2- or ER+, Her2+) 1939 62 30
21.1 % 24.0 % 27.3 %
Basal (ER-, PR-, Her2-) 1306 16 4
14.2 % 6.2 % 3.6 %
Her2-positive (ER-, PR-, Her2+) 536 16 4
5.8 % 6.2 % 3.6 %
Missing 16,744 332 161    
64.5 % 56.3 % 59.4 %
AGE cat (ordinal) 50 or younger 6932 162 101 0.99 0.0037 0.0029
27.0 % 27.8 % 37.3 %
Older than 50 and not more than 70 16,083 344 151
62.6 % 59.0 % 55.7 %
Older than 70 2674 77 19
10.4 % 13.2 % 7.0 %
Missing 251 7 0    
1.0 % 1.2 % 0.0 %
AGE Mean 57.1 57.9 54.3 0.41 0.028 0.024
St.dev. 10.8 11.1 11.0
Total   25,940 590 271    
  1. BCAC Breast Cancer Association Consortium, ER estrogen receptor, PR progesterone receptor, Her2 human epidermal growth factor receptor 2, EGFR epidermal growth factor receptor, CK5/6 cytokeratin 5/6, TP53 tumor protein 53, LumA luminal A, LumB luminal B
  2. *Categories Medullary, Mucinous and Papillary were combined for the Cochran-Mantel-Haenszel test
  3. #Categories Mixed, Tubular, Medullary, Mucinous and Papillary were combined for the Cochran-Mantel-Haenszel test
  4. The “missing” category included also rare forms of breast cancer, which did not belong to the named categories: 1179 non-carriers, 25 p.I157T carriers and 9 c.1100delC carriers
  5. Tumor subtypes are defined according to ER, PR and Her2 expression following the St Gallen 2013 guidelines [34]
  6. Italics is used to indicate the proportion of study subjects in each category. E.G. 'ER-positive/all with known ER-status' or 'missing/all study subjects'